Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: Single center experience on talc poudrage morbidity: focus on high talc dosage. | Leuzzi et al. Journal of Cardiothoracic Surgery 2011 6 87 http content 6 1 87 JCTS JOURNAL OF CARDIOTHORACIC SURGERY LETTERS TO THE EDITOR Open Access Single center experience on talc poudrage morbidity focus on high talc dosage z- I 1 1 1 1 Giovanni Leuzzi Maria Letizia Vita Venanzio Porziella Maria Teresa Congedo and Alfredo Cesario Abstract Malignant pleural effusion MPE is a common clinical problem of concern for most of the pneumologists and thoracic surgeons. A general consensus regarding the use of talc poudrage in treatment of MPE exists but only few studies analyzed in detail talc insufflation related pulmonary morbidity. In particular ARDS talc-related is caused by physical and chemical effects of the small talc particles 50 particle size 15 gm and its occurrence is independent from the underlying disease the quantity of talc used or the technique of talc instillation. In our series we observed 3 cases only of talc-related lung injury. This data strongly confirm the low rate of talc-related lung injury after talc poudrage in treatment of MPE regardless the amount of talc insufflated. Letter to the editor We read with great interest the report by Barbetakis et al 1 on morbidity mortality and life expectancy following thoracoscopic talc insufflation. Malignant pleural effusion MPE is a common clinical problem of concern for most of the pneumologists and thoracic surgeons. In the US the annual incidence of MPE is estimated to be cases and several studies suggest that exudative effusions are by large 42 - 77 caused by malignancy 2 . A general consensus regarding the use of talc poudrage in treatment of MPE exists only few studies analyzed in detail talc insufflation related pulmonary morbidity. The most common side effects are pleuritic chest pain and mild fever. However very serious and potentially fatal adverse events albeit unusual 1 to 9 in published series 3 as such as an adult respiratory distress syndrome
